Exicure Financials
| XCUR Stock | USD 27.69 0.95 3.55% |
Exicure |
Understanding current and past Exicure Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Exicure's financial statements are interrelated, with each one affecting the others. For example, an increase in Exicure's assets may result in an increase in income on the income statement.
Exicure Stock Summary
Exicure competes with Ikena Oncology, Eliem Therapeutics, HCW Biologics, RenovoRx, and Tempest Therapeutics. Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois. Exicure operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs people.Specialization | Healthcare, Biotechnology |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US30205M1018 |
| CUSIP | 30205M101 30205M200 30205M309 |
| Location | Illinois; U.S.A |
| Business Address | 2430 North Halsted |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.exicuretx.com |
| Phone | 847 673 1700 |
| Currency | USD - US Dollar |
Exicure Key Financial Ratios
| Return On Equity | -1.44 | ||||
| Return On Asset | -0.26 | ||||
| Target Price | 2.0 | ||||
| Beta | 1.28 |
Exicure Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Exicure's current stock value. Our valuation model uses many indicators to compare Exicure value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Exicure competition to find correlations between indicators driving Exicure's intrinsic value. More Info.Exicure is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Exicure by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Exicure Systematic Risk
Exicure's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Exicure volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Exicure correlated with the market. If Beta is less than 0 Exicure generally moves in the opposite direction as compared to the market. If Exicure Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Exicure is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Exicure is generally in the same direction as the market. If Beta > 1 Exicure moves generally in the same direction as, but more than the movement of the benchmark.
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Exicure is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Exicure has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Exicure's financials are consistent with your investment objective using the following steps:- Review Exicure's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Exicure's liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Exicure's financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Exicure's stock is overvalued or undervalued.
Exicure November 27, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Exicure help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Exicure. We use our internally-developed statistical techniques to arrive at the intrinsic value of Exicure based on widely used predictive technical indicators. In general, we focus on analyzing Exicure Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Exicure's daily price indicators and compare them against related drivers.
| Downside Deviation | 7.18 | |||
| Information Ratio | 0.2775 | |||
| Maximum Drawdown | 95.22 | |||
| Value At Risk | (10.95) | |||
| Potential Upside | 47.72 |
Additional Tools for Exicure Stock Analysis
When running Exicure's price analysis, check to measure Exicure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Exicure is operating at the current time. Most of Exicure's value examination focuses on studying past and present price action to predict the probability of Exicure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Exicure's price. Additionally, you may evaluate how the addition of Exicure to your portfolios can decrease your overall portfolio volatility.